Electronic Resource
[s.l.]
:
Nature Publishing Group
Nature biotechnology
23 (2005), S. 556-557
ISSN:
1546-1696
Source:
Nature Archives 1869 - 2009
Topics:
Biology
,
Process Engineering, Biotechnology, Nutrition Technology
Notes:
[Auszug] Monoclonal antibodies (mAbs) have become the protein therapeutics of choice for targeting cancer, and increasingly for other indications. Recent setbacks involving the withdrawal of Biogen Idec's (Cambridge, MA, USA) IgG4 mAb (Tysabri, natalizumab) for use in multiple sclerosis, however, serve to ...
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1038/nbt0505-556
Permalink
|
Location |
Call Number |
Expected |
Availability |